SONY

Product Data Sheet

Brilliant Violet 785™ anti-human CD196 (CCR6)

Catalog # / Size:	2367105 / 25 tests 2367110 / 100 tests
Clone:	G034E3
Isotype:	Mouse IgG2b, κ
Immunogen:	CCR6-transfected cells
Reactivity:	Human, Non-human primate, Other
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Workshop Number:	HCDM listed
Concentration:	Lot-specific



Human peripheral blood lymphocytes were stained with CD19 FITC and CD196 (clone G034E3) Brilliant Violet 785™.

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.



For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products.
Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

Description: CCR6, also known as CD196, is a chemokine receptor that is expressed on immature dendritic cells, B lymphocytes, and memory T cells. CCR6 binds CCL20, although members of the β defensin family also bind CCR6 with a lower affinity. CCR6 positive cells, and its ligand CCL20, have been detected in numerous organs, especially the secondary lymphoid organ. CCL20 is selectively made by the follicle-associated epithelium (FAE) overlying Peyers Patches (PPs) and isolated lymphoid follicles (ILFs). CCL20 contributes to the recruitment of CCR6-expressing B cells to these structures. In humans, CCR6 can function to mediate arrest of T cells on dermal endothelial cells and is highly expressed on T cells resident in both normal and psoriatic skin. CCR6 and/or CCL20 have been implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Human T cells that are able to produce IL-17 express CCR6. It suggests that CCL20 and CCR6 have a role in inflammatory diseases by recruiting Th17 cells to target tissues.

Antigen References:

1. Zaballos A, *et al.* 1996. *Biochem. Bioph. Res. Co.* 227:846.
2. Yang D, *et al.* 1999. *Science* 286:525.
3. MacDonald KG, et al. 2007. *Am. J. Pathol.* 170:1229.
4. Homey B, *et al.* 2000. *J. Immunol.* 164:6621.
5. Hirota K, *et al.* 2007. *J. Exp. Med.* 204:2803.
6. Singh SP, *et al.* 2008. *J. Immunol.* 180:214.

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products.